Skip to main content

Table 3 Baseline characteristics of patients included in the INPULSIS® pooled data set, experiencing no acute exacerbations or experiencing ≥ 1 acute exacerbation (analysis 2)

From: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

 No acute exacerbations (n = 998)≥ 1 acute exacerbation (n = 63)
Women, n (%)209 (20.9)11 (17.5)
Age, years66.6 (8.0)69.3 (7.5)
Time since IPF diagnosis, years1.6 (1.3)1.8 (1.4)
Ethnicity, n (%)
 White578 (57.9)30 (47.6)
 Black2 (0.2)0 (0)
 Asian304 (30.5)18 (28.6)
 Missing114 (11.4)15 (23.8)
BMI, kg/m228.0 (4.6)27.1 (4.1)
Smoking history, n (%)
 Non-smoker281 (28.2)15 (23.8)
 Ex-smoker670 (67.1)48 (76.2)
 Current smoker47 (4.7)0 (0)
Comorbidities, n (%)
 PH30 (3.0)0 (0)
 COPD25 (2.5)2 (3.2)
 Lung cancera4 (0.4)0 (0)
 GERD231 (23.1)17 (27.0)
 CAD85 (8.5)3 (4.8)
FVC, % predicted80.2 (17.8)69.4 (15.0)
FEV1/FVC ratio81.5 (5.9)84.2 (5.5)
DLCO, % predicted47.5 (13.3)42.6 (15.2)
  1. Data are shown in mean (standard deviation), unless otherwise indicated. aLung cancer includes malignant lung neoplasm, squamous cell carcinoma of lung, non-small-cell lung cancer and metastatic lung adenocarcinoma
  2. BMI body mass index, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, PH pulmonary hypertension